(UroToday.com) Dr. Laurence Albiges discussed the evolving landscape of first-line systemic treatment in metastatic renal cell carcinoma (mRCC) at the European Association of Urology’s (EAU) 2021 annual meeting’s controversies in onco-urology session. Dr. Albiges started by highlighting the new guidelines adapted from the EAU and ESMO guidelines for RCC, using the IMDC risk classification to select treatment options. A summary of the adapted guidelines are as follows: